![Li Yang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Li Yang
Corporate Officer/Principal presso Harbin Pacific Biopharmaceutical Co., Ltd.
Posizioni attive di Li Yang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Corporate Officer/Principal | 01/06/1999 | - |
Storia della carriera di Li Yang
Precedenti posizioni note di Li Yang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Direttore/Membro del Consiglio | 16/01/2016 | - |
Formazione di Li Yang
Harbin Normal University | Undergraduate Degree |
Victoria University (Switzerland) | Masters Business Admin |
Statistiche
Distribuzione geografica
Cina | 4 |
Svizzera | 2 |
Posizioni
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Health Technology |
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Health Technology |
- Borsa valori
- Insiders
- Li Yang
- Esperienza